Key Highlights
- MRNA shares traded up 5.78% to $240.00, versus a prior close of $226.89.
- Full Phase 3 INTerpath-001 melanoma data are due at ESMO.
- BofA raised its target to $220 and Oddo BHF to $251 from $170.
- Q3 results are due Nov. 6, with options implying a move near 19%.
- The stock sits near a 52-week high of $242.29.
Investors Position Ahead of Full Phase 3 Melanoma Data
Moderna (NASDAQ:MRNA) shares traded up 5.78% to $240.00 as investors positioned for full Phase 3 data on intismeran, its personalized cancer vaccine co-developed with Merck (NYSE:MRK). The INTerpath-001 melanoma readout is due at ESMO.
The stock is near its 52-week high of $242.29, against a 52-week low of $22.28, and market capitalization is about $95.82 billion. It is also outpacing a firm healthcare sector.
Targets Rise, but Consensus Remains at Hold
Analyst targets keep moving up, with BofA raising its target to $220 with a Neutral rating and Oddo BHF lifting its target to $251 from $170. Consensus is still Hold, with an average target well below the current price.
Risks include insider selling by the company's president, continued losses, with earnings per share at a loss of $8.15, valuation concerns and a recent selloff in vaccine stocks.
Q3 Results on Nov. 6 Bring Guidance and Flu Vaccine Signals
Moderna reports Q3 on Nov. 6, and options imply a one-day move near 19%. Investors will look for a reiteration of 2026 guidance of revenue growth up to 10%, cash costs of about $4 billion and year-end cash of $4.7 billion to $5.2 billion. Management has said Q3 should be about 55% of second-half revenue.
Other items include early launch signals for its new flu and flu/COVID combination vaccines, the new Chief Operating Officer role and an Analyst Day reportedly set for Nov. 12.
Melanoma Data and Earnings Will Test the Rally
With the stock up sharply this year, the melanoma readout and the Nov. 6 report are the next tests of whether the rally can hold.






Please wait processing your request...